Session: <i>C. difficile</i>: Clinical and Outcomes (IDWeek 2012 Meeting)

Thursday, October 18, 2012: 12:30 PM-2:00 PM

Room: SDCC Poster Hall F-H

Topical Category: N. Infection Epidemiology and Prevention and P. Pediatric and Perinatal Infections

Tracks: Epidemiology and Infection Control, Pediatric ID

Presentations:

293

Does Prolonging the Duration of C. difficile Infection Treatment Decrease Recurrences in Patients Receiving Concurrent Antibiotics?
Rafael Ponce-Terashima, MD ; Nuntra Suwantarat, MD ; Sirisha Kundrapu, M.D. ; Venkata Sunkesula, M.D, M.S ; Curtis J. Donskey, MD

Posters

Rafael's Poster-2.pdf (390.9 kB)

294	Predicting recurrence following a first episode of Clostridium difficile infection Jasmin Islam ; Vishal Navani ; Elizabeth Cheek ; Chakravarthi Rajkumar ; Jonathan Cohen ; Martin Llewelyn Posters J.ISLAM IDSA.pdf (582.5 kB)

295

Predicting the Risk of Clostridium difficile Infections Following an Outpatient Visit: Development and External Validation of a Pragmatic, Prognostic Risk Score
Jennifer Kuntz, PhD ; Eric Johnson, PhD ; Marsha Raebel, PharmD ; Amanda Petrik ; Xiuhai Yang ; Micah Thorp, DO, MPH ; Steven Spindel, MD ; Nancy Neil, PhD ; David Smith, PhD

296	Use of Vancomycin for the Management of Clostridium difficile Infection in U.S. Children's Hospitals Hayden Schwenk, MD ; Dionne A. Graham, PhD ; Tanvi Sharma, MD ; Thomas J. Sandora, MD, MPH Posters IDWeekPoster(vF2).pdf (900.4 kB)

297	Attributable Outcomes of Clostridium difficile Infection among Hospitalized Children Julia F. Shaklee, MD ; Rui Xiao, PhD ; A. Russell Localio, PhD ; Susan Coffin, MD, MPH ; Theoklis Zaoutis, MD, MSCE Posters IDWeek_Poster_2012.pdf (667.3 kB)

298	Examining clinical outcomes in a cohort of incident Clostridium difficile (CDI) patients using parametric survival models Eric Lofgren, MSPH ; Rebekah W. Moehring, MD ; David J. Weber, MD, MPH, FIDSA, FSHEA ; Deverick J. Anderson, MD, MPH

299	Clinical Impact of Probiotics Among Patients Receiving Antibiotics with High Risk of Acquiring Clostridium difficile Infections Justine Dickson, PharmD ; Tai-Tsang Chen, PhD ; Whitney (Yu-Hui) Hung, Pharm D, BCPS Posters Slide1.png (291.7 kB)

300	Patient Attitudes Towards the Use of Intestinal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile Infection Jonathan Zipursky, BScH ; Tivon Sidorsky, MD, MBA ; Kathryn Kirkland, MD, FSHEA Posters IDWeekPoster-10-06-2012 TS final edit with JZ.pdf (384.6 kB)

301

Characterizing the Cytokine Response to Clostridium difficile Infection
Krishna Rao, MD ; Seth Walk, MS, PhD ; Dejan Micic, MD ; Nicole Falkowski ; Jill Mogle, LPN ; Cathrin Ring, MS ; John Erb-Downward, PhD ; Vincent B Young, MD, PhD ; Gary Huffnagle, PhD ; David Aronoff, MD, FIDSA

Posters

10_11_12 Luminex IDWeek_2012 poster draft.pdf (1.7 MB)

302

Development and Optimization of High Throughput Assays to Measure Neutralizing Antibodies against Clostridium difficile Toxins
Jinfu Xie ; Julie Zorman ; Lani Indrawati ; Melanie Horton ; Keri Soring ; Joseph Antonello ; Yuhua Zhang ; Su Wang ; Susan Secore ; Lorraine Hernandez ; Matthew Miezeiewski ; Julie Skinner ; Jean-Luc Bodmer ; Jon Heinrichs, PhD

Posters

IDWeek poster Sep2012 final.pdf (206.1 kB)

303	Treatment of Refractory Clostridium difficile With Nitazoxanide Samuel Aitken, Pharm.D. ; Michael Ruggero, Pharm.D. ; Nilesh Amin, Pharm.D. ; Jeffrey Topal, MD Posters Aitken SL, et al. Nitazoxanide for refractory CDI_ID Week 2012.pdf (1.3 MB)

304

Evaluation of a Clostridium difficile Infection Treatment Guideline with Clinical Pharmacy and Medical Microbiology Involvement at a Major Canadian Teaching Hospital
Shirley S.T. Yeung, BSc(Pharm) ; Janice Yeung, PharmD ; Tim T.Y. Lau, PharmD ; Theodore Steiner, MD ; Leslie Forrester, BA(Hons), MA, MSc ; Mandeep Saran, PharmD ; Elizabeth Bryce, MD FRCPC

Posters

CDI_Poster_SYEUNG.pdf (240.5 kB)

305	The Kinetics of the Leukocyte Response during Clostridium difficile Infection (CDI) Anne Bantle, MD ; W. Kemper Alston, MD, MPH Posters Cdiff Poster PDF.pdf (407.9 kB)

306	Management of Clostridium difficile infection (CDI). Results from a Pan-European Survey: Perceptions and Reality Mark Wilcox, MD ; Ed J. Kuijper, MD, PhD ; Annie Jones, MSc ; David Bradshaw, BSc (Hons) ; Christian Felter, MD Posters V5 Survey Poster Testing.ppt.pdf (341.9 kB)

307	Antimicrobial choice in Clostridium difficile infection: Taking recurrence risk into account Christian Felter, MD ; Christopher Longshaw, PhD ; Annie Jones, MSc ; David Bradshaw, BSc (Hons) Posters V3 Survey Poster Recurrence Risk_FINAL 15OCT2012.pdf (85.4 kB)

308	A systematic review of risk factors for recurrences of Clostridium difficile infection Claire Nour Abou Chakra, MSc ; Jacques P�pin, M.D. ; Stephanie Sirard, M.Sc. ; Louis Valiquette, MD

309

Outcomes of Clostridium difficile infection in Veterans with Spinal Cord Injury/Disorder (SCI/D)
Charlesnika Evans, MPH, PhD ; Stuart Johnson, MD, FIDSA ; Stephen Burns, MD ; Linda Poggensee, MS ; Bridget Smith, PhD ; Barry Goldstein, MD, PhD ; Stephen Kralovic, MD, MPH ; Dale Gerding, MD, FIDSA

Posters

Evans cdiff 10-2012.pdf (244.6 kB)

310	Validation of a Clostridium difficile recurrence score David Eyre, BM, BCh ; Tim Peto, MB BS, DPhil ; David Wyllie, PhD ; Kate Dingle, PhD ; David Griffiths, BSc ; John Finney ; Lily O'Connor, BSc ; Alison Vaughan, BSc ; Derrick Crook, MB, BCh ; Mark Wilcox, MD ; A. Sarah Walker, PhD

311	Clostridium difficile Infection Among Autologous Hematopoietic Cell Transplantation Recipients:� Risk factor and Outcomes Analysis Kari Neemann, MD ; Fausto Loberiza Jr., MD. MS ; Alison Freifeld, MD Posters IDSA Poster C Diff Auto HSCT.png (513.0 kB)

312	Predicting the Risk for Hospital-onset Clostridium difficile Infection at the Time of Inpatient Admission Ying P. Tabak, PhD ; Xiaowu Sun, PhD ; Carlos Nunez, MD ; RS Johannes, MD, MS Posters IDWeek 2012-Predicting the Risk for HO-CDI on Admission 9-29-12.pdf (1.7 MB)

313	Management of Clostridium difficile infections: First results of the pan-European PROHIBIT Survey Sonja Hansen, MD ; Walter Zingg, MD ; Frank Schwab, MSc ; Michael Behnke, MSc ; Hugo Sax, MD ; Didier Pittet, MD, MS ; Petra Gastmeier, MD ; Prohibit Consortium

314

The Impact of Cefepime as First Line Therapy for Neutropenic Fever on Clostridium difficile rates among Hematologic and Oncologic Patients
Eavan Muldoon, MB, BCh, MD ; Lauren Epstein, MD ; Tanya Logvinenko ; Susan Murray ; Shira Doron, MD ; David Snydman, MD, FIDSA

Posters

cefepimeIDSA 9th oct.pdf (273.7 kB)

315

Colonoscopic versus nasogastric fecal transplantation for treatment of Clostiridium difficile infection: a review of the literature with pooled analysis
Ricardo Postigo, MD ; Jong Hun Kim, MD

Posters

Colonoscopic versus nasogastric fecal transplantation for treatment of Clostiridium difficile infection a review of the literature with pooled analysis.pdf (262.9 kB)

316	Development and Validation of a Recurrent Clostridium difficile (CDI) Risk Prediction Model Marya Zilberberg, MD, MPH ; Kimberly Reske, MPH ; Margaret Olsen, PhD, MPH ; Yan Yan, MD, PhD ; Sheila Thomas, PharmD ; Erik Dubberke, MD, MSPh

317	Recurrence of C. difficile infection (CDI): A risk-stratified analysis of Fidaxomicin vs Vancomycin Basem Alraddadi, MBBS ; Lauren Epstein, MD ; David Snydman, MD, FIDSA ; Yoav Golan, MD MS Posters IDSA2012 alraddadi Final.pdf (662.6 kB)

318	Impact of the 2010 SHEA-IDSA Practice Guidelines in Understanding Risk for Clostridium difficile Infection Jason Leung, BS ; Robert Burke, RN, MA ; Dale Ford, RN, MPH ; Gale Garvin, RN, MEd ; Cathy Korn, RN, MPH ; Carol Sulis, MD ; Nahid Bhadelia, MD, MA

319	Adherence to and Outcomes Associated with a Clostridium difficile Infection Guideline at a Large Teaching Institution RaeAnna C. Zatarski, Pharm.D. ; Sarah M. Wieczorkiewicz, Pharm.D., BCPS

CME Credits:

See more of: Poster Abstract Session

<< Previous Session | Next Session >>